EmbryoScope+ by Vitrolife is a time-lapse system with an integrated incubator for undisturbed culture and improved selection of embryos.
The new system, which has a large capacity in combination with a small footprint, offers efficient workflow and optimized usage of clinical resources. It is scheduled for introduction at the upcoming European Society of Human Reproduction and Embryology (ESHRE) conference, July 3-6, in Helsinki, Finland.
EmbryoScope+ builds on the same technology as the company´s EmbryoScope, but with a larger capacity for 15 patients with up to 16 embryos per patient in a single instrument.
“The time-lapse market is growing and we believe that time-lapse has the potential to become a standard tool in IVF treatments,” Thomas Axelsson, CEO at Vitrolife, said in a statement.
Time-lapse technology enables the entire development of the embryo to be studied, increasing the probability of choosing the embryo with the best chances of leading to pregnancy. The use of time-lapse technology has been documented to improve clinical outcomes.
Vitrolife develops, produces and markets medical devices for assisted reproduction. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes.
The company, headquartered in Gothenburg, Sweden, employs some 360 workers and sells products in more than 10 markets. It maintains offices in the U.S., Australia, France, Italy, U.K., China, Japan, Hungary, Denmark and Germany.
